Dr. Stefan Jungblut

Dr. Stefan Jungblut has over 20 years of work experience in the pharmaceutical and healthcare industry. Their most recent role is as a Senior Clinical Research Manager at TFS HealthScience - Contract Research Organization, starting in April 2022. Prior to this, they worked as the Local Study Associate Director (DACH Oncology) at AstraZeneca from October 2020 to March 2022.

From 2018 to 2020, Dr. Jungblut served as a Clinical Project & Cooperation Manager at LMU / LMU Clinic. In the same year, they also worked at Glenwood GmbH as a Pharmacovigilance Officer (EU QPPV) & Project Manager Serialisation, where they were responsible for setting up and maintaining pharmacovigilance systems and managing projects related to product design, pricing, and GDPR implementation.

Earlier in their career, Dr. Jungblut held various positions including Project Manager (CNS Clinical Trials/IT) at MedAvante, Clinical Project Manager (Medical Devices) at International Medical Research, Pharmacovigilance Manager and Medical Reviewer at International Breast Cancer Study Group (IBCSG), and Clinical Data Management at Clinical Trial Center (University Hospital Zurich).

Dr. Stefan also served as Treasurer and Committee Member of the Postdoc Association at the University of Basel (Biozentrum) from 2009 to 2011. Dr. Jungblut began their career as a Pharmaceutical Aid at Boehringer Ingelheim in 2000.

Dr. Stefan Jungblut's education history is as follows:

1. In 2020, they attended CEplus for a degree in In-Vitro Diagnostics in Clinical Drug Trials.

2. In 2018, they completed a Basic and Advanced Training for MDR Clinical Trials at MedTech Pharma.

3. Also in 2018, they obtained a degree in SCRUM Master and Product Owner from TÜV Sued.

4. In 2017, they attended ATV for a degree in Business Manager, with a field of study in Business, Management, Marketing, and Related Support Services.

5. In 2015, they completed a degree in Clinical Study Management at CenTrial.

6. In 2013, they obtained a degree in EudraVigilance from the European Medicines Agency.

7. In 2011, they attended the University Hospital of Basel, Clinical Trial Unit, for a degree in Clinical Investigator.

8. Also in 2011, they completed a degree in Project Management and Leadership at the University of Basel, with a field of study in Project Management/Organisation, Conflict & People Management, Communication.

9. In the same year, they obtained a degree in Regulatory Affairs from the University of Basel, with a field of study in Basic Regulatory Affairs Principles.

10. From 2009 to 2011, they pursued a Postdoctorate degree in Neurophysiology and Cell/molecular biology at the Dep. Biomedicine, Pharmazentrum University of Basel.

11. From 2006 to 2009, they completed their Doctor of Philosophy (Ph.D.) in Biophysical Chemistry at the Biozentrum, University of Basel.

12. In 2003 and 2004, they conducted a Research Project & Thesis in Bioorganic Chemistry at Heriot-Watt University, Edinburgh.

13. From 2000 to 2005, they obtained a Diploma in Biochemistry from the University of Bayreuth, with a field of study in Biochemistry, Bioorganic Chemistry, Biophysics, and Molecular Biology.